Advench Pharmaceutical Private Limited

Rabishield is a human monoclonal antibody preparation developed for passive immunization against rabies virus infection. It is specifically designed as an alternative to conventional rabies immunoglobulin (RIG) and is used in combination with rabies vaccine for post-exposure prophylaxis. Rabishield provides immediate passive immunity by neutralizing the rabies virus at the site of infection, thereby preventing the virus from entering the central nervous system. Unlike human or equine rabies immunoglobulin, Rabishield offers standardized potency, higher safety, and eliminates risks of blood-borne infections since it is manufactured through recombinant monoclonal antibody technology. It is indicated for individuals exposed to potentially rabid animals through bites, scratches, or mucosal contamination. Administered by infiltration into and around the wound, with the remainder given intramuscularly, Rabishield ensures rapid protective coverage until the active immunity from rabies vaccine develops. The product is highly stable, requires standard cold chain storage between 2–8°C, and has a favorable safety profile. It is widely recommended by healthcare providers, public health programs, and hospitals as part of modern rabies management. With its ease of use, consistent quality, and reliable protection, Rabishield has become a preferred choice for life-saving rabies post-exposure prophylaxis.